Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Case mix adjusted ratio of mean functional outcome scores (EPIC-26) of PSA-detected compared to symptomatic prostate cancer survivorsc

From: Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study

Respondent characteristics at diagnosis Number of cases Adjusted mean ratio (95% CI) – symptomatic vs. PSA-detected a
Urinary incontinence Urinary irritation/ obstruction Bowel function Sexual function Vitality/ hormonal function
All respondents 32,588 0.96 (0.96-0.97)** 0.95 (0.95-0.96)** 0.97 (0.97-0.98)** 0.90 (0.88-0.92)** 0.96 (0.96-0.96)**
Age group
 Under 75 24,566 0.96 (0.95-0.96)** 0.95 (0.95-0.96)** 0.97 (0.97-0.98)** 0.91 (0.89-0.93)** 0.96 (0.95-0.96)**
 75 and over 8017 0.97 (0.95-0.98)** 0.96 (0.95-0.97)** 0.98 (0.97-0.99)** 0.91 (0.86-0.96)* 0.96 (0.95-0.98)**
Stage
 I/II 17,818 0.96 (0.95-0.96)** 0.95 (0.95-0.96)** 0.97 (0.97-0.98)** 0.91 (0.88-0.93)** 0.96 (0.96-0.97)**
 III 6643 0.97 (0.95-0.98)** 0.96 (0.95-0.97)** 0.98 (0.97-0.99)** 0.88 (0.83-0.94)** 0.96 (0.94-0.97)**
 IV 3535 0.98 (0.96-1.00) 0.96 (0.95-0.98)** 0.99 (0.97-1.01) 0.86 (0.76-0.96)* 0.95 (0.92-0.97)**
Gleason score
 2-6 8083 0.97 (0.96-0.98)** 0.95 (0.94-0.96)** 0.97 (0.97-0.98)** 0.93 (0.90-0.96)** 0.97 (0.96-0.97)**
 7 12,917 0.95 (0.95-0.96)** 0.96 (0.95-0.96)** 0.97 (0.96-0.98)** 0.88 (0.85-0.91)** 0.88 (0.85-0.91)**
 8-10 6077 0.97 (0.96-0.99)* 0.96 (0.95-0.97)** 0.99 (0.98-1.00) 0.87 (0.80-0.93)* 0.95 (0.93-0.96)**
Treatment type b
 Any surgery 9710 0.97 (0.96-0.99)* 0.96 (0.96-0.97)** 0.97 (0.97-0.98)** 0.93 (0.89-0.97)* 0.96 (0.96-0.97)**
 Any EBRT 12,780 0.96 (0.95-0.97)** 0.96 (0.95-0.96)** 0.97 (0.97-0.98)** 0.84 (0.80-0.87)** 0.95 (0.94-0.96)**
 Any ADT 14,016 0.96 (0.95-0.97)** 0.96 (0.95-0.96)** 0.98 (0.97-0.98)** 0.86 (0.82-0.90)** 0.95 (0.94-0.96)**
 Monitoring only 5378 0.95 (0.94-0.96)** 0.94 (0.93-0.94)** 0.97 (0.97-0.98)** 0.91 (0.88-0.94)** 0.97 (0.96-0.98)**
  1. Notes
  2. CI Confidence Interval, EBRT External Beam Radiotherapy, ADT Androgen Deprivation Therapy
  3. *p < 0.05, **p < 0.001 after Bonferroni correction for multiple comparisons
  4. a Determined using multivariable log-linear model adjusted for other variables in the table plus nation, deprivation, number of comorbidities, BMI, ethnicity, marital status and employment status. An adjusted mean score of less than one can be interpreted to mean that symptomatic patients have poorer functionality than PSA-detected patients
  5. b Men may have more than one type of treatment
  6. c Alive 18-42 months after diagnosis